Competitor Analysis: CXCR and CXCL Agonists and AntagonistsLa Merie PublishingNovember 1, 2009 30 Pages - SKU: LAM2504530 |
|
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
5/11/2012 | published by: Kalorama Information
The drug discovery process is long, arduous and costly, which has driven outsourcing in this field. The first phase is discovery of a lead compound, a molecule that affects biological function by binding to a
|
more...
|
$3,995.00
|
|
Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019
5/21/2012 | published by: GlobalData
Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Summary GlobalData, the industry analysis specialist, has released its new report, “Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report
|
more...
|
$3,995.00
|
|
Pulmonary Arterial Hypertension – Pipeline Review, H1 2012
4/19/2012 | published by: Global Markets Direct
Pulmonary Arterial Hypertension – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Pulmonary Arterial Hypertension - Pipeline Review, H1 2012', provides an overview of the Pulmonary Arterial Hypertension therapeutic pipeline. This report provides information on the therapeutic
|
more...
|
$500.00
|
|
Metastatic Hepatocellular Carcinoma (HCC) – Pipeline Review, H1 2012
4/19/2012 | published by: Global Markets Direct
Metastatic Hepatocellular Carcinoma (HCC) – Pipeline Review, H1 2012 Summary Global Markets Direct’s, 'Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H1 2012', provides an overview of the Metastatic Hepatocellular Carcinoma (HCC) therapeutic pipeline. This report provides information
|
more...
|
$500.00
|
|
Hemorrhoids Global Clinical Trials Review, H1, 2012
4/25/2012 | published by: GlobalData
Hemorrhoids Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Hemorrhoids Global Clinical Trials Review, H1, 2012 provides data on the Hemorrhoids clinical trial scenario. This report provides elemental information and data relating to the
|
more...
|
$1,000.00
|
|
Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors and by the compound strategy of Antibodies. Each of these three individual parts is evaluated
|
more...
|
$5,175.00
|
|
Triple Analysis: Apoptosis, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors and by the compound strategy of Antibodies. Each of these three individual parts is evaluated
|
more...
|
$5,175.00
|
|
Triple Analysis: Breast Cancer, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Breast Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Each of these three individual parts is
|
more...
|
$5,175.00
|
|
Triple Analysis: Cancer Vaccines, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Cancer Vaccines and Protein Kinase Inhibitors and by the compound strategy of Antibodies. Each of these three individual parts is
|
more...
|
$5,175.00
|
|
Triple Analysis: Colorectal Cancer, Protein Kinase Inhibitors and Antibodies
5/1/2012 | published by: BioSeeker Group AB
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Colorectal Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Each of these three individual parts is
|
more...
|
$5,175.00
|
Related Markets
Drug Discovery Reports
- Retinal Vein Occlusion Therapeutics - Pipeline Assessment and Market Forecasts to 2019
- Patient Perspectives - Patient Reported Outcomes Drive Drug Development, but Improving Patient Involvement Remains a Challenge
- Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
- Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
- Non-Alcoholic Steatohepatitis Global Clinical Trials Review, H1, 2012
